biotech / news / / Devdiscourse
Novo Nordisk reported a first-quarter adjusted operating profit that surpassed analyst expectations.
Novo Nordisk's first-quarter adjusted operating profit exceeded analyst forecasts.
KEY POINTS
- Novo Nordisk is increasingly focusing on its new weight-loss pill to drive growth.
- The firm faces intensifying competition from Eli Lilly in the obesity treatment market.
- The obesity sector is experiencing a notable price war as firms battle for market share.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →